Compare SID & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SID | ABUS |
|---|---|---|
| Founded | 1941 | 2005 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 833.8M | 836.0M |
| IPO Year | 2002 | 2008 |
| Metric | SID | ABUS |
|---|---|---|
| Price | $0.51 | $4.04 |
| Analyst Decision | Sell | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $1.17 | N/A |
| AVG Volume (30 Days) | ★ 10.8M | 2.3M |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 1.13 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | N/A | $1,208.75 |
| Revenue Next Year | $1.87 | N/A |
| P/E Ratio | ★ N/A | $3.61 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $0.55 | $3.50 |
| 52 Week High | $2.20 | $5.45 |
| Indicator | SID | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 24.87 | 46.55 |
| Support Level | N/A | $3.59 |
| Resistance Level | $1.34 | $4.52 |
| Average True Range (ATR) | 0.07 | 0.20 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 1.23 | 72.58 |
Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations port concessions and fleets of road transport vehicles. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.